Kiromic Biopharma Valuation
| KRBPDelisted Stock | USD 2.68 0.07 2.55% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Kiromic Biopharma secures a last-minute Real Value of $2.55 per share. The latest price of the firm is $2.68. Our model forecasts the value of Kiromic Biopharma from analyzing the firm fundamentals such as Return On Equity of -11.3, shares owned by insiders of 3.91 %, and Current Valuation of 9.55 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kiromic Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Kiromic Biopharma is based on 3 months time horizon. Increasing Kiromic Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Kiromic Biopharma's intrinsic value may or may not be the same as its current market price of 2.68, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.68 | Real 2.55 | Hype 2.68 | Naive 2.65 |
The intrinsic value of Kiromic Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kiromic Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kiromic Biopharma helps investors to forecast how Kiromic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiromic Biopharma more accurately as focusing exclusively on Kiromic Biopharma's fundamentals will not take into account other important factors: Kiromic Biopharma Total Value Analysis
Kiromic Biopharma is now forecasted to have valuation of 9.55 M with market capitalization of 2.15 M, debt of 9.41 M, and cash on hands of 6.51 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kiromic Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.55 M | 2.15 M | 9.41 M | 6.51 M |
Kiromic Biopharma Asset Utilization
One of the ways to look at asset utilization of Kiromic is to check how much profit was generated for every dollar of assets it reports. Kiromic Biopharma secures a negative usage of assets of -0.92 %, losing $0.009194 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kiromic Biopharma shows how discouraging it operates for each dollar spent on its assets.Kiromic Biopharma Ownership Allocation
Over half of Kiromic Biopharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions.Kiromic Biopharma Profitability Analysis
Net Loss for the year was (34.73 M) with profit before overhead, payroll, taxes, and interest of 0.About Kiromic Biopharma Valuation
The delisted stock valuation mechanism determines Kiromic Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Kiromic Biopharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kiromic Biopharma. We calculate exposure to Kiromic Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kiromic Biopharma's related companies.Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Kiromic Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Kiromic Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 544.5 K |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |